Clinical Trials

Multiple Myeloma, Recurrence

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

43 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT05669846 2026-03-09

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05681195 2026-03-03

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

15 enrolled

Neoplasms, Recurrence

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02974647 2026-02-27

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

83 enrolled

Lymphoma, Recurrence

NCT01356290 2026-02-23

MEMMAT

232 enrolled

Ependymoma, Medulloblastoma, Recurrence

NCT05530421 2026-02-23

SELVEDge

33 enrolled

Multiple Myeloma, Recurrence

NCT07263438 2026-02-13

Phenix

59 enrolled

Glioblastoma, Recurrence

NCT06297226 2026-02-10

QUINTESSENTIAL

230 enrolled

Multiple Myeloma, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

15 enrolled

Recurrence

NCT06854653 2026-02-03

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

115 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05629702 2026-01-30

ARISTOCRAT

120 enrolled

Brain Neoplasms, Marijuana Abuse, Glioblastoma, Recurrence

NCT06660368 2026-01-29

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

52 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT05046314 2026-01-14

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Sarcoma

Recurrence, Sarcoma, Ewing

NCT05922501 2026-01-14

ISABELA

50 enrolled

Multiple Myeloma, Recurrence

NCT07337421 2026-01-13

Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors

Carcinoma, Hepatocellular, Recurrence

NCT07337460 2026-01-13

Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors

Carcinoma, Hepatocellular, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

90 enrolled

Multiple Myeloma, Recurrence

NCT06232655 2025-12-19

Cladribine Venetoclax in Monocytic AML

20 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

23 enrolled

Multiple Myeloma, Recurrence

NCT04204850 2025-12-03

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

20 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

27 enrolled

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Hodgkin Disease, Recurrence

NCT07254754 2025-11-28

LATE-R-GEL-23

45 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT07082686 2025-11-21

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

68 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT07051486 2025-11-17

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

60 enrolled

Gynecologic

Uterine Cervical Neoplasms, Recurrence

NCT06421675 2025-11-14

EMBRACE

40 enrolled

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

43 enrolled

Multiple Myeloma, Recurrence

NCT06534437 2025-09-29

JASPIS-01

178 enrolled

Aggression, Lymphoma, Non-Hodgkin, Recurrence

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07126236 2025-08-17

REPIFIR

80 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04684147 2025-08-08

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

100 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06356883 2025-08-07

Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma

120 enrolled

Glioblastoma, Recurrence

NCT07105579 2025-08-06

Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia

31 enrolled

Leukemia, Recurrence

NCT07022002 2025-08-03

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

340 enrolled

Neoplasms, Recurrence

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

56 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT06651853 2025-07-23

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

22 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04868162 2025-07-08

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

116 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT06802315 2025-06-25

BMT-13

MyeloidOther hematologic neoplasm

38 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

130 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06971380 2025-05-14

Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

180 enrolled

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma, Recurrence

NCT06686108 2025-05-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

LymphoidOther hematologic neoplasm

59 enrolled

Leukemia, Recurrence, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

39 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

160 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT05241093 2025-04-10

A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

18 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06918912 2025-04-09

LORELY

50 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05313243 2025-03-20

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma